GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Other Long Term Assets

Biogen (MEX:BIIB) Other Long Term Assets : MXN17,729 Mil (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Other Long Term Assets?

Biogen's other long-term assets for the quarter that ended in Mar. 2025 was MXN17,729 Mil.

Biogen's quarterly other long-term assets declined from Sep. 2024 (MXN31,506 Mil) to Dec. 2024 (MXN18,451 Mil) but then stayed the same from Dec. 2024 (MXN18,451 Mil) to Mar. 2025 (MXN17,729 Mil).

Biogen's annual other long-term assets declined from Dec. 2022 (MXN53,723 Mil) to Dec. 2023 (MXN28,408 Mil) and declined from Dec. 2023 (MXN28,408 Mil) to Dec. 2024 (MXN18,451 Mil).

Biogen Other Long Term Assets Historical Data

The historical data trend for Biogen's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Long Term Assets Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84,909.00 68,816.27 53,723.18 28,408.10 18,451.04

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26,485.96 29,249.88 31,506.45 18,451.04 17,729.08

Biogen Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Other Long Term Assets
Comparable Companies
OGN AMRN MDCX SCLX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.